El informe
Análisis profundos sobre financiación de empresas, estrategias de crecimiento e insights de mercado de los negocios más innovadores del mundo
6 informes y contando
Kinaset Therapeutics Raises $103M Series B | Inhalable JAK Inhibitor for Asthma
Biotech Kinaset Therapeutics secures $103 million Series B for inhalable pan-JAK inhibitor treating severe asthma.
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.
Annexon Biosciences raises $125M Series D at $750M valuation
Annexon Biosciences raises $125M in Series D at $750M valuation. Classical complement pathway inhibitors...
Crystalys Therapeutics Raises $205M Series A to Transform Biotech
Crystalys Therapeutics has secured $205M Series A in funding to accelerate growth and innovation in the biotech sector. Clinical-stage biopharmaceutical company developing next-generation oral URAT1 inhibitor dotinurad for the treatment of ...
Annexon Biosciences Raises $125M in Series D
Annexon Biosciences, a Biotech company based in 180 Kimball Way, South San Francisco, CA 94080, has raised $125M in Series D at a $750M valuation led by GV, Alta Partners, Omega Funds, Cowen Healthcare Investments, Redmile Group.
Braveheart Bio Raises $185 million in Series A
Braveheart Bio, a Biotechnology company based in San Francisco CA, has raised $185 million in Series A at a Undisclosed led by Andreessen Horowitz.
Mostrando 6 informes • Página 1 • Categoría: all
Mantente a la vanguardia del mercado
Recibe insights semanales en tu bandeja de entrada. Sin spam, solo inteligencia.